The 44th SOLACI Regional Sessions – 15th South Cone Region took place in a hybrid setting (F2F and online) in Asuncion, Paraguay, between June 30 and July 1, 2022. It was a successful event that featured prestigious national and international guests and a world class scientific program. Next, we share some of the presentations held<a href="https://solaci.org/en/2022/09/14/watch-the-highlighted-presentations-of-the-paraguay-sessions-2022/" title="Read more" >...</a>
The treatment of ST-segment elevation acute coronary syndromes (STEACS) is undoubtedly reperfusion therapy with primary percutaneous coronary intervention. Similarly, nobody doubts that the pretreatment with more stronger antiplatelet agents has a role in such a treatment. In certain sites, unfractionated heparin (UFH) pretreatment is also administered before the patient enters the cath lab; its aim<a href="https://solaci.org/en/2022/09/12/heparin-pretreatment-in-steacs-treatment-a-new-old-ally/" title="Read more" >...</a>
According to the European Society of Cardiology (ESC Guidelines 2021) an early invasive strategy is recommended (<24h) for high-risk patients with acute coronary syndrome with no ST elevation (NSTE-ACS), namely patients presenting a rise or fall in cardiac troponin, dynamic ST- or T-wave changes and GRACE risk score >140. Early intervention (<2h) is reserved for<a href="https://solaci.org/en/2022/06/09/when-is-the-ideal-timing-for-nste-acs-percutaneous-intervention/" title="Read more" >...</a>
Many years of developing and waiting have led us to the latest guidelines published by ACC/AHA together with other societies. This is the first document exclusively dedicated to the assessment and diagnosis of acute chest pain. In this regard, we can safely say this is no mere update of a previous set of guidelines, but<a href="https://solaci.org/en/2021/11/02/first-guidelines-focused-specifically-on-chest-pain-management/" title="Read more" >...</a>
Patients with acute myocardial infarction presenting lesions in multiple vessels is not associated with reduced infarct size in non-culprit lesions, even when functionally significant. Animal models suggest brief periods of ischemia in non-infarct territories (non-culprit) might protect culprit territory thanks to remote ischemic preconditioning. This pre-conditioning, according to this perspective, would reduce reperfusion injury and<a href="https://solaci.org/en/2021/05/11/new-unexpected-data-on-non-culprit-vessels-in-mi/" title="Read more" >...</a>
Data from recent observational randomized studies suggest that most patients with asymptomatic severe aortic stenosis will eventually receive an indication for valve replacement. Mortality in this “asymptomatic” population is caused not only by sudden death, but also by cardiac death. Early intervention may prevent these deaths as a consequence of aortic stenosis symptoms. Researchers<a href="https://solaci.org/en/2020/10/30/asymptomatic-severe-aortic-stenosis-when-should-we-intervene/" title="Read more" >...</a>
We thank all the presenters of the Peru Sessions2018 who shared their presentations to contribute to our mission of promoting scientific dissemination in the field of Interventional Cardiology in Latin American level. See them below. Dr. Marcelo Halac: “Enfermedad Cardiovascular en la Mujer: Características que la hacen diferente”. (Spanish version) <a href="https://solaci.org/en/2020/01/13/take-a-look-at-the-presentations-of-the-peru-sessions2018/" title="Read more" >...</a>
PASCAL transcatheter valve repair system for mitral regurgitation has shown feasibility and safety to treat patients with grade 3+ or 4+, regardless etiology. Regurgitation grade was significantly reduced, and this was accompanied by clinical improvement in functional class, exercise capacity and quality of life. This study soon to be published in J Am Coll Cardiol<a href="https://solaci.org/en/2019/07/15/new-promising-alternatives-for-mitral-regurgitation/" title="Read more" >...</a>
The Fourth Universal Definition of Myocardial Infarction is a document developed jointly by the European Society of Cardiology (ESC), the American College of Cardiology (ACC), the American Heart Association (AHA), and the World Heart Federation (WHF). The Fourth Definition was necessary for multiple reasons, including increasingly higher troponin sensitivity. While troponin obviously does not<a href="https://solaci.org/en/2019/01/30/the-ten-commandments-for-the-fourth-universal-definition-of-infarction/" title="Read more" >...</a>
It seems that a LDL level of 70 mg/dL is no longer low enough for high-risk secondary patients; in consequence, this study attempted to set a new target, one that appears almost impossible to reach: 40 mg/dL or lower. This study, simultaneously presented at the European Society of Cardiology Congress 2017 and published in The Lancet, showed<a href="https://solaci.org/en/2017/09/13/fourier-efficacy-of-evolocumab-for-ultra-low-ldl-levels/" title="Read more" >...</a>